OTCMKTS:PPCB

Propanc Biopharma Competitors

$0.21
-0.01 (-4.27 %)
(As of 04/20/2021 05:19 PM ET)
Add
Compare
Today's Range
$0.21
Now: $0.21
$0.23
50-Day Range
$0.21
MA: $0.28
$0.45
52-Week Range
$0.18
Now: $0.21
$22.00
Volume10,738 shs
Average Volume134,571 shs
Market Capitalization$1.12 million
P/E RatioN/A
Dividend YieldN/A
Beta1.9

Competitors

Propanc Biopharma (OTCMKTS:PPCB) Vs. BCTXF, FWDG, ISCO, ABMC, AMBS, and AKRXQ

Should you be buying PPCB stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Propanc Biopharma, including BriaCell Therapeutics (BCTXF), FutureWorld (FWDG), International Stem Cell (ISCO), American Bio Medica (ABMC), Amarantus BioScience (AMBS), and Akorn (AKRXQ).

BriaCell Therapeutics (OTCMKTS:BCTXF) and Propanc Biopharma (OTCMKTS:PPCB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.

Earnings & Valuation

This table compares BriaCell Therapeutics and Propanc Biopharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A$-3,680,000.00N/AN/A
Propanc BiopharmaN/AN/A$-4,740,000.00N/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for BriaCell Therapeutics and Propanc Biopharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BriaCell Therapeutics0000N/A
Propanc Biopharma0000N/A

Insider & Institutional Ownership

0.1% of BriaCell Therapeutics shares are held by institutional investors. 0.0% of Propanc Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares BriaCell Therapeutics and Propanc Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BriaCell TherapeuticsN/AN/A-786.77%
Propanc BiopharmaN/AN/A-4,812.81%

Risk and Volatility

BriaCell Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Propanc Biopharma has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500.

Summary

BriaCell Therapeutics beats Propanc Biopharma on 3 of the 5 factors compared between the two stocks.

FutureWorld (OTCMKTS:FWDG) and Propanc Biopharma (OTCMKTS:PPCB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares FutureWorld and Propanc Biopharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FutureWorldN/AN/AN/AN/AN/A
Propanc BiopharmaN/AN/A$-4,740,000.00N/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for FutureWorld and Propanc Biopharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FutureWorld0000N/A
Propanc Biopharma0000N/A

Risk & Volatility

FutureWorld has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Propanc Biopharma has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500.

Profitability

This table compares FutureWorld and Propanc Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FutureWorldN/AN/AN/A
Propanc BiopharmaN/AN/A-4,812.81%

International Stem Cell (OTCMKTS:ISCO) and Propanc Biopharma (OTCMKTS:PPCB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.

Analyst Ratings

This is a summary of recent ratings for International Stem Cell and Propanc Biopharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
International Stem Cell0000N/A
Propanc Biopharma0000N/A

Risk and Volatility

International Stem Cell has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Propanc Biopharma has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.

Valuation and Earnings

This table compares International Stem Cell and Propanc Biopharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Stem Cell$9.47 million0.50$-4,260,000.00N/AN/A
Propanc BiopharmaN/AN/A$-4,740,000.00N/AN/A

International Stem Cell has higher revenue and earnings than Propanc Biopharma.

Profitability

This table compares International Stem Cell and Propanc Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
International Stem Cell-55.56%N/A-72.21%
Propanc BiopharmaN/AN/A-4,812.81%

Summary

International Stem Cell beats Propanc Biopharma on 3 of the 5 factors compared between the two stocks.

Propanc Biopharma (OTCMKTS:PPCB) and American Bio Medica (OTCMKTS:ABMC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Risk & Volatility

Propanc Biopharma has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, American Bio Medica has a beta of -1.45, indicating that its stock price is 245% less volatile than the S&P 500.

Profitability

This table compares Propanc Biopharma and American Bio Medica's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Propanc BiopharmaN/AN/A-4,812.81%
American Bio Medica-18.99%N/A-35.34%

Valuation and Earnings

This table compares Propanc Biopharma and American Bio Medica's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Propanc BiopharmaN/AN/A$-4,740,000.00N/AN/A
American Bio Medica$3.65 million0.97$-680,000.00N/AN/A

American Bio Medica has higher revenue and earnings than Propanc Biopharma.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Propanc Biopharma and American Bio Medica, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Propanc Biopharma0000N/A
American Bio Medica0000N/A

Summary

American Bio Medica beats Propanc Biopharma on 3 of the 5 factors compared between the two stocks.

Propanc Biopharma (OTCMKTS:PPCB) and Amarantus BioScience (OTCMKTS:AMBS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Propanc Biopharma and Amarantus BioScience, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Propanc Biopharma0000N/A
Amarantus BioScience0000N/A

Volatility and Risk

Propanc Biopharma has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, Amarantus BioScience has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.

Profitability

This table compares Propanc Biopharma and Amarantus BioScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Propanc BiopharmaN/AN/A-4,812.81%
Amarantus BioScienceN/AN/AN/A

Insider and Institutional Ownership

0.0% of Amarantus BioScience shares are held by institutional investors. 0.0% of Propanc Biopharma shares are held by company insiders. Comparatively, 10.3% of Amarantus BioScience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Propanc Biopharma and Amarantus BioScience's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Propanc BiopharmaN/AN/A$-4,740,000.00N/AN/A
Amarantus BioScienceN/AN/AN/AN/AN/A

Summary

Amarantus BioScience beats Propanc Biopharma on 3 of the 4 factors compared between the two stocks.

Propanc Biopharma (OTCMKTS:PPCB) and Akorn (OTCMKTS:AKRXQ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Profitability

This table compares Propanc Biopharma and Akorn's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Propanc BiopharmaN/AN/A-4,812.81%
Akorn-54.01%-5.13%-0.49%

Volatility & Risk

Propanc Biopharma has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500. Comparatively, Akorn has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.

Valuation & Earnings

This table compares Propanc Biopharma and Akorn's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Propanc BiopharmaN/AN/A$-4,740,000.00N/AN/A
Akorn$682.43 million0.01$-226,770,000.00N/AN/A

Propanc Biopharma has higher earnings, but lower revenue than Akorn.

Institutional and Insider Ownership

0.1% of Akorn shares are held by institutional investors. 0.0% of Propanc Biopharma shares are held by insiders. Comparatively, 3.9% of Akorn shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Propanc Biopharma and Akorn, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Propanc Biopharma0000N/A
Akorn0000N/A


Propanc Biopharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BCTXF
BriaCell Therapeutics
0.0N/AN/A$4.59 millionN/A-0.01
FutureWorld logo
FWDG
FutureWorld
0.5$0.00-0.0%$4.56 millionN/A0.00
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.63-9.5%$4.07 million$9.47 million0.00High Trading Volume
Gap Up
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.09-6.0%$3.75 million$3.65 million0.00News Coverage
Gap Up
Amarantus BioScience logo
AMBS
Amarantus BioScience
0.0$0.01-20.2%$3.63 millionN/A0.00
AKRXQ
Akorn
0.1$0.03-0.0%$3.60 million$682.43 million-0.01
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01-1.4%$3.36 millionN/A0.00Gap Down
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.14-0.0%$2.88 millionN/A0.00
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01-0.0%$2.85 million$2 million0.00
RespireRx Pharmaceuticals logo
RSPI
RespireRx Pharmaceuticals
0.5$0.04-3.8%$2.82 millionN/A-0.09News Coverage
Gap Up
VVUSQ
VIVUS
0.6$0.12-0.0%$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.45-9.0%$1.87 millionN/A0.00Gap Up
NSPX
Inspyr Therapeutics
0.5$0.01-14.0%$1.83 millionN/A0.00
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.04-0.6%$1.78 million$530,000.000.00
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02-2.5%$1.70 million$20,000.00-0.79Gap Down
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.50-11.0%$1.57 millionN/A0.00News Coverage
Gap Up
Cardax logo
CDXI
Cardax
0.0$1.95-2.6%$1.55 million$710,000.000.00High Trading Volume
Gap Up
MLNTQ
Melinta Therapeutics
0.2$0.11-0.0%$1.51 million$96.43 million0.00
HSTC
HST Global
0.8$0.26-7.7%$1.36 millionN/A0.00Gap Down
WWHC
W World
0.8$4.90-8.2%$1.33 millionN/A0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03-0.4%$1.29 million$8.73 million0.00Gap Up
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.25-79.4%$1.12 millionN/A-2.76Upcoming Earnings
Gap Down
AOXG
Aoxing Pharmaceutical
0.5$0.01-13.0%$991,000.00N/A0.00Gap Down
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04-1.3%$978,000.00N/A0.00Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01-3.3%$928,000.00N/A0.00Gap Up
ATRX
Adhera Therapeutics
0.0$0.06-7.1%$872,000.00$250,000.000.00Gap Down
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07-8.1%$865,000.00N/A0.00Gap Up
PXYN
Praxsyn
0.6$0.00-10.0%$763,000.00N/A0.00Gap Down
SPHS
Sophiris Bio
0.1$0.02-6.7%$739,000.00N/A0.00Gap Up
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05-0.0%$572,000.00$1.90 million0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.03-26.0%$547,000.00N/A0.00Gap Down
TRPXD
Therapix Biosciences
0.0$9.20-0.5%$460,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.16-5.6%$399,000.00N/A0.00Gap Up
SKVI
Skinvisible
0.7$0.10-11.6%$376,000.00$40,000.000.00
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01-2.0%$366,000.00N/A0.00Gap Down
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01-0.0%$343,000.00N/A0.00
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47-3.7%$338,000.00$36.55 million0.00Gap Up
PZRXQ
PhaseRx
0.2$0.03-35.2%$332,000.00N/A0.00
WDBG
Woodbrook Group
0.0$1.60-0.0%$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.08-21.2%$183,000.00N/A0.00
OREXQ
Orexigen Therapeutics
0.4$0.01-26.4%$100,000.00$33.71 million0.00Gap Up
MetaStat logo
MTST
MetaStat
0.0$0.01-0.7%$82,000.00$20,000.000.00
AXMP
AXM Pharma
0.2$0.00-0.0%$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00-0.0%$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00-0.0%$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02-3.3%$7,000.00$110,000.000.00Gap Up
Acusphere logo
ACUS
Acusphere
0.0$0.05-2.2%$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.10-17.3%$0.00N/A0.00Gap Down
AOBI
American Oriental Bioengineering
0.4$1.50-0.0%$0.00N/A0.00
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.